BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16000290)

  • 41. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
    Forero-Torres A; Shen S; Breitz H; Sims RB; Axworthy DB; Khazaeli MB; Chen KH; Percent I; Besh S; LoBuglio AF; Meredith RF
    Cancer Biother Radiopharm; 2005 Aug; 20(4):379-90. PubMed ID: 16114986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
    Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Lin Y; Hedin N; Pantelias A; Axworthy D; Stone D; Hamlin DK; Wilbur DS; Press OW
    Blood; 2006 Jul; 108(1):328-36. PubMed ID: 16556891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
    Urbano N; Papi S; Ginanneschi M; De Santis R; Pace S; Lindstedt R; Ferrari L; Choi S; Paganelli G; Chinol M
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
    Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
    J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
    Press OW; Corcoran M; Subbiah K; Hamlin DK; Wilbur DS; Johnson T; Theodore L; Yau E; Mallett R; Meyer DL; Axworthy D
    Blood; 2001 Oct; 98(8):2535-43. PubMed ID: 11588052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
    Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
    Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel preparation and characterization of a trastuzumab-streptavidin conjugate for pre-targeted radionuclide therapy.
    Hainsworth JE; Harrison P; Mather SJ
    Nucl Med Commun; 2006 May; 27(5):461-71. PubMed ID: 16609358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
    Weiden PL; Breitz HB
    Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
    Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
    Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
    Zhang M; Yao Z; Garmestani K; Axworthy DB; Zhang Z; Mallett RW; Theodore LJ; Goldman CK; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Blood; 2002 Jul; 100(1):208-16. PubMed ID: 12070029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody.
    Zhang M; Yao Z; Saga T; Sakahara H; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
    J Nucl Med; 1998 Jan; 39(1):30-3. PubMed ID: 9443734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
    Kenanova V; Olafsen T; Williams LE; Ruel NH; Longmate J; Yazaki PJ; Shively JE; Colcher D; Raubitschek AA; Wu AM
    Cancer Res; 2007 Jan; 67(2):718-26. PubMed ID: 17234783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
    Park SI; Shenoi J; Frayo SM; Hamlin DK; Lin Y; Wilbur DS; Stayton PS; Orgun N; Hylarides M; Buchegger F; Kenoyer AL; Axtman A; Gopal AK; Green DJ; Pagel JM; Press OW
    Clin Cancer Res; 2011 Dec; 17(23):7373-82. PubMed ID: 21976541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.